



Universiteit
Leiden
The Netherlands

Mechanistic early phase clinical pharmacology studies with disease-modifying drugs for neurodegenerative disorders

Vissers, M.F.J.M.

Citation

Vissers, M. F. J. M. (2023, June 21). *Mechanistic early phase clinical pharmacology studies with disease-modifying drugs for neurodegenerative disorders*. Retrieved from <https://hdl.handle.net/1887/3621076>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3621076>

Note: To cite this publication please use the final published version (if applicable).

MECHANISTIC EARLY PHASE CLINICAL PHARMACOLOGY STUDIES WITH
DISEASE-MODIFYING DRUGS FOR NEURODEGENERATIVE DISORDERS

*For Mia and Lotta
never stop exploring*

MECHANISTIC EARLY PHASE
CLINICAL PHARMACOLOGY STUDIES
WITH DISEASE-MODIFYING DRUGS
FOR NEURODEGENERATIVE
DISORDERS

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op woensdag 21 juni 2023
klokke 15.00 uur

door
Maurits Frederick Johan Maria Vissers
geboren te Amsterdam
in 1987

© Maurits F.J.M. Vissers, 2023

Design: Caroline de Lint, Den Haag (caro@delint.nl)

Images: Generated using DALL·E, OpenAI software (labs.openai.com).

Publication of this thesis was financially supported by the foundation Centre
for Human Drug Research in Leiden, the Netherlands.

Promotor

Prof. dr. G.J Groeneveld

Co-promotor

Dr. J.A.A.C. Heuberger

Leden promotiecommissie

Prof dr. J.J. van Hilten

Prof. dr. T. van Gelder

Prof. dr. E.L. Swart (*Amsterdam Universitair Medisch Centrum*)

Dr. M. van Es (*Universitair Medisch Centrum Utrecht*)

CHAPTER 1

7 Introduction

CHAPTER 2

23 Targeting for success: demonstrating proof-of-concept with mechanistic early phase clinical pharmacology studies for disease-modification in neurodegenerative disorders

CHAPTER 3

61 Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: randomized, placebo-controlled, double-blind phase 1/1B studies in healthy subjects and patients

CHAPTER 4

87 A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls

CHAPTER 5

113 LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease

CHAPTER 6

155 General discussion and conclusion

APPENDICES

165 Nederlandse samenvatting

177 Curriculum vitae

178 List of publications